News

Feb 1

TestAVec researchers devise new protocols to generate high titre HIV-1 lentivirus vectors in a cost efficient and scalable method

TestAVec researchers, lead by CSO Professor Michael Themis, have devised new protocols for making high titre HIV-1 lentivirus particles...

Dec 25, 2023

Happy holidays from the TestAVec team

From all of us here at TestAVec, we wish you a happy holiday season and new year. Time to enjoy the festive period and go into 2024 to...

Dec 18, 2023

TestAVec and Vidiia accelerating DNA damage testing platform

TestAVec and Vidiia are working together to accelerate DiNARep to commercial testing. DiNARep identifies if patients are able to repair...

Dec 15, 2023

FDA cancer concern over CAR-T gene therapy

Recently, the US Food and Drug Administration (FDA) has expressed that it is investigating cases of blood cancer in CAR-T therapies....

Dec 11, 2023

DNA repair test takes 'hit and miss' out of chemotherapy

Better results for patients on chemotherapy, radiotherapy and gene therapy A personalised test that tells how well chemotherapy,...